Lista de obras - Cirino Botta - Dominio Público Uruguay

A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.

artículo científico publicado en 2015

A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.

artículo científico publicado en 2016

A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.

artículo científico publicado en 2014

A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?

artículo científico publicado en 2013

A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?

artículo científico publicado en 2015

An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma

scientific article published on 18 November 2019

Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.

artículo científico publicado en 2017

Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients

artículo científico publicado en 2016

Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation

artículo científico publicado en 2021

Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro.

artículo científico publicado en 2011

Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing

artículo científico publicado en 2021

Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility

artículo científico publicado en 2021

Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab

scientific article published on 16 May 2019

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials

artículo científico publicado en 2020

GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up

scientific article published on 08 November 2019

Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized

artículo científico publicado en 2014

Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.

artículo científico publicado en 2015

Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients.

artículo científico publicado en 2016

Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.

artículo científico publicado en 2012

Immunologic microenvironment and personalized treatment in multiple myeloma.

artículo científico publicado en 2013

Immunomodulatory activity of microRNAs: potential implications for multiple myeloma treatment

artículo científico publicado en 2017

Immunotherapy of colorectal cancer: new perspectives after a long path.

artículo científico publicado en 2016

In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection

artículo científico publicado en 2022

Inflammatory status affects the antitumor activity of poly-epitope-peptide vaccination against the thymidylate synthase in metastatic colo-rectal cancer patients enrolled in TSPP/VAC-1 Phase Ib trial.

artículo científico publicado en 2015

Influence of the Fabrication Accuracy of Hot-Embossed PCL Scaffolds on Cell Growths

artículo científico publicado en 2020

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts

artículo científico publicado en 2015

Iron Metabolism in the Tumor Microenvironment—Implications for Anti-Cancer Immune Response

artículo científico publicado en 2021

Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation

artículo científico publicado en 2016

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells

artículo científico publicado en 2017

Mouse models of multiple myeloma: technologic platforms and perspectives.

artículo científico publicado en 2018

Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities

artículo científico

Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients

artículo científico publicado en 2017

OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes

artículo científico publicado en 2016

Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials

artículo científico publicado en 2014

Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients.

artículo científico publicado en 2015

Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients

artículo científico publicado en 2011

Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients.

artículo científico publicado en 2015

Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab

scientific article published on 16 December 2019

Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).

artículo científico publicado en 2017

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma

artículo científico publicado en 2019

Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials

artículo científico publicado en 2012

Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.

artículo científico publicado en 2015

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

scientific article published on 14 April 2020

Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer

artículo científico publicado en 2016

Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine.

artículo científico publicado en 2018

The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis

artículo científico publicado en 2018

The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells.

artículo científico publicado en 2018

The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response.

artículo científico publicado en 2016

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma

scientific article published on 21 March 2019

Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination

scientific article published on 08 October 2019

Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse

artículo científico publicado en 2016

Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma

artículo científico publicado en 2011

miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma

artículo científico publicado en 2020

miR-22 suppresses DNA ligase III addiction in multiple myeloma

artículo científico publicado en 2018

miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease

artículo científico publicado en 2013

miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.

artículo científico

Lista de obras de Cirino Botta

A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.

A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.

A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.

A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?

A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?

An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma

Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.

Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients

Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation

Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro.

Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing

Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility

Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials

GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up

Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized

Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.

Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients.

Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.

Immunologic microenvironment and personalized treatment in multiple myeloma.

Immunomodulatory activity of microRNAs: potential implications for multiple myeloma treatment

Immunotherapy of colorectal cancer: new perspectives after a long path.

In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection

Inflammatory status affects the antitumor activity of poly-epitope-peptide vaccination against the thymidylate synthase in metastatic colo-rectal cancer patients enrolled in TSPP/VAC-1 Phase Ib trial.

Influence of the Fabrication Accuracy of Hot-Embossed PCL Scaffolds on Cell Growths

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts

Iron Metabolism in the Tumor Microenvironment—Implications for Anti-Cancer Immune Response

Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells

Mouse models of multiple myeloma: technologic platforms and perspectives.

Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities

Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients

OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes

Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials

Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients.

Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients

Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients.

Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab

Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma

Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials

Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer

Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine.

The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis

The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells.

The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response.

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma

Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination

Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse

Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma

miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma

miR-22 suppresses DNA ligase III addiction in multiple myeloma

miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease

miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.